Journal of Neuro-Oncology

, Volume 95, Issue 3, pp 421–426 | Cite as

Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy

  • Florian Clatot
  • Géraldine Philippin-Lauridant
  • Matthieu-John Ouvrier
  • Tony Nakry
  • Sophie Laberge-Le-Couteulx
  • Cécile Guillemet
  • Corinne Veyret
  • Emmanuel Blot
Clinical Study - Patient Study

Abstract

Leptomeningeal meningitis occurs in approximately 5% of metastatic breast cancers, and there is no standard treatment for this complication. We retrospectively analyzed the clinical data and cerebrospinal fluid of 24 patients treated with high-dose intrathecal methotrexate for breast cancer leptomeningeal meningitis (BLM). Cytologic response (CSF cytology without neoplastic cells after treatment) was observed in 11 patients (46%) and related to survival (P = 0.005). In addition, clinical symptoms improved in all 11 patients who had a cytologic response and in 7 patients (54%) without cytologic response (P = 0.02). The predictive value of cytologic response needs further confirmation. Cytologic response could be helpful in the management of intrathecal chemotherapy in patients with BLM.

Keywords

Metastatic breast cancer Leptomeningeal metastasis Survival Intrathecal chemotherapy Prognostic factor 

References

  1. 1.
    Jayson GC, Howell A (1996) Carcinomatous meningitis in solid tumours. Ann Oncol 7(8):773–786CrossRefPubMedGoogle Scholar
  2. 2.
    Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY (2005) Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 75(1):85–99. doi:10.1007/s11060-004-8101-x CrossRefPubMedGoogle Scholar
  3. 3.
    Chamberlain MC, Kormanik PR (1997) Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 35(1):55–64. doi:10.1023/A:1005803918194 CrossRefPubMedGoogle Scholar
  4. 4.
    Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11(3):561–569CrossRefPubMedGoogle Scholar
  5. 5.
    Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S et al (2008) A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208–215. doi:10.1215/15228517-2007-059 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chamberlain MC (2008) Neoplastic meningitis. Oncologist 13(9):967–977. doi:10.1634/theoncologist.2008-0138 CrossRefPubMedGoogle Scholar
  7. 7.
    Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T et al (1996) Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 77(7):1315–1323. doi:10.1002/(SICI)1097-0142(19960401)77:7<1315::AID-CNCR14>3.0.CO;2-4 CrossRefPubMedGoogle Scholar
  8. 8.
    Boogerd W, Hart AA, van der Sande JJ, Engelsman E (1991) Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67(6):1685–1695. doi:10.1002/1097-0142(19910315)67:6<1685::AID-CNCR2820670635>3.0.CO;2-M CrossRefPubMedGoogle Scholar
  9. 9.
    Rudnicka H, Niwinska A, Murawska M (2007) Breast cancer leptomeningeal metastasis—the role of multimodality treatment. J Neurooncol 84(1):57–62. doi:10.1007/s11060-007-9340-4 CrossRefPubMedGoogle Scholar
  10. 10.
    Kim DY, Lee KW, Yun T, Park SR, Jung JY, Kim DW et al (2003) Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 33(12):608–612. doi:10.1093/jjco/hyg118 CrossRefPubMedGoogle Scholar
  11. 11.
    Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394–3402PubMedGoogle Scholar
  12. 12.
    Orlando L, Curigliano G, Colleoni M, Fazio N, Nole F, Martinelli G et al (2002) Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 22(5):3057–3059PubMedGoogle Scholar
  13. 13.
    Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40(18):2726–2733. doi:10.1016/j.ejca.2004.08.012 CrossRefPubMedGoogle Scholar
  14. 14.
    Moots PL, Harrison MB, Vandenberg SR (1995) Prolonged survival in carcinomatous meningitis associated with breast cancer. South Med J 88(3):357–362CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Florian Clatot
    • 1
  • Géraldine Philippin-Lauridant
    • 1
  • Matthieu-John Ouvrier
    • 1
  • Tony Nakry
    • 1
  • Sophie Laberge-Le-Couteulx
    • 2
  • Cécile Guillemet
    • 1
  • Corinne Veyret
    • 1
  • Emmanuel Blot
    • 1
  1. 1.Département d’Oncologie MédicaleCentre Henri-BecquerelRouen CedexFrance
  2. 2.Service d’Anatomie et Cytologie PathologiquesCentre Henri-BecquerelRouen CedexFrance

Personalised recommendations